Method of use of radicicol for treatment of immunopathological disorders
US5731343A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Feb 24, 1995 |
| Grant date | Mar 24, 1998 |
| Priority date | — |
| Expiry date | Feb 24, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/365
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method of treating an immunopathological disorder having an etiology associated with production of a proinflammatory agent, by administering a compound of the formula: ##STR1## where R1 and R2 are independently H or --COR3; R3 is H, 1-50C alkyl, 1-20C alkoxy, 2-30C alkenyl, 2-30C alkenyloxy, 2-10 alkynyl, 6-14C aryl or aryloxy, a 5-6 membered heterocycle (containing 1-3 N, O and/or S heteroatoms and optionally fused to an aryl group), 3-8C cycloalkyl (optionally fused to aryl) or 5-8C cycloalkenyl; and R4 is a halogen. Examples of such proinflammatory agents include interleukin-1 (IL-1), interleukin-6 (IL-6), interferon-.gamma. (IFN-.gamma.), tumor necrosis factor-.alpha. (TNF-.alpha.), granulocyte macrophage-colony stimulating factor (GM-CSF), the growth related gene KC, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), macrophage chemotactic protein (MCP), inducible nitric oxide synthetase (iNOS), macrophage inflammatory protein (MIP), tissue factor (TF), phosphotyrosine phosphatase (PTPase), and endotoxin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.